Vaccine maker stocks fall on reports Trump plans to tap RFK Jr. to lead HHS
Shares of vaccine makers fell as President-elect Donald Trump nominated Robert F. Kennedy Jr., a prominent vaccine skeptic, to lead the Department of Health and Human Services.  Health policy experts have said a second Trump term could allow Kennedy to elevate anti-vaccine rhetoric.
Trump Expected to Select RFK Jr. to Lead HHS, Politico Reports
Kennedy Jr. and Republican presidential nominee and former U.S. President Donald Trump greet each other at a campaign event sponsored by conservative group Turning Point USA, in Duluth, Georgia, U.S.,
RFK Jr., Vaccine Skeptic, Is Trump's Choice for Health Secretary
President-elect Donald Trump tapped Robert F. Kennedy Jr. to lead the Department of Health and Human Services.
Trump Taps Vaccine Skeptic RFK Jr. to Lead HHS. Moderna, Novavax Stock Slide.
Donald Trump nominated Robert F. Kennedy Jr., a vaccine skeptic and harsh critic of federal health agencies, to be his Secretary of Health and Human Services. Trump announced the nomination in a post on Truth Social.
Trump Selects RFK Jr. for Health Secretary; Vaccine Stocks Fall
President-elect Donald Trump said he’s tapping Robert F. Kennedy Jr., to run the Department of Health and Human Services, a move that would elevate a prominent vaccine skeptic and pharmaceutical industry critic to a top role on federal health policy.
Vaccine maker stocks tumble after Trump picks RFK Jr. for health secretary
Shares of prominent vaccine makers plunged Thursday after President-elect Donald Trump announced his pick of Robert F. Kennedy Jr. to be the next secretary of the Department of Health and Human Services.
Trump Taps Anti-Vaxxer RFK Jr. To Lead Health And Human Services
Kennedy Jr. as The United States Secretary of Health and Human Services (HHS),” Trump wrote on social media. “For too long, Americans have been crushed by the industrial food complex and drug companies who have engaged in deception,
Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Zacks.com on MSN3d
Novavax to Report Q3 Earnings: Here's What to Expect
Novavax NVAX is scheduled to report third-quarter 2024 earnings on Nov. 12, before the opening bell. In the last reported ...
Novavax Stock is Slipping After the Vaccine Maker Cut its Outlook Again
Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.
Novavax sees weak Covid vaccine sales, convinced Sanofi can do better
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...
Novavax: Navigating Fiscal Challenges and Strategic Shifts Amid COVID Vaccine Market Uncertainty
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
bovnews5h
What Factors Have Led to Novavax Inc (NVAX) Stock Trading -67.46% Below Its 52-Week High?
On Wednesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $7.76 which represents a decrease of $-0.70 or -8.27% from the prior close of $8.46. The stock opened at $8.44 and touched a low ...
Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates
Novavax (NVAX) delivered earnings and revenue surprises of 12.64% and 47.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Outlook For Novavax
Analysts are estimating that Novavax will report an earnings per share (EPS) of $-0.87. Anticipation surrounds Novavax's ...
Novavax: Balancing Potential and Risk Amid Strategic Shifts and Uncertain Market Outlook
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
Novavax, Inc.: Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights
U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates Achieved total ...